🇺🇸 FDA
Pipeline program

Immune Globulin Intravenous (Human), 10%

160601

Phase 3 small_molecule completed

Quick answer

Immune Globulin Intravenous (Human), 10% for Primary Immunodeficiency Diseases (PID) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Primary Immunodeficiency Diseases (PID)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials